All Trials

A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adolescents and adults with advanced measurable HLRCC-associated RCC or sporadic/non-HLRCC papillary RCC (prior VEGF therapy allowed, but no prior bevacizumab or PD-1/PD-L1 in the advanced setting), including patients with treated/stable brain mets. Treatment combines bevacizumab (anti-VEGF), erlotinib (EGFR TKI), and atezolizumab (anti–PD-L1) given in 21-day cycles until progression/toxicity, aiming to improve response and disease control.

ClinicalTrials.gov ID: NCT04981509

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with MGRS due to plasma cell dyscrasia, including NDMM with cast nephropathy or other biopsy-proven MGRS lesions (excluding AL amyloidosis), impaired renal function/proteinuria, and no prior anti–plasma cell therapy receive CyBorD plus subcutaneous daratumumab. Daratumumab is an anti‑CD38 monoclonal antibody; treatment includes 8 induction cycles with optional ASCT and, if ineligible, maintenance bortezomib/dexamethasone every other week plus daratumumab every 4 weeks.

ClinicalTrials.gov ID: NCT06083922

A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with measurable, folate receptor-α–positive persistent/recurrent endometrial cancer (including uterine serous, grade 2–3 endometrioid, carcinosarcoma with high-grade serous or grade 2/3 endometrioid components, and clear cell), ECOG 0–1, and ≤3 prior lines for recurrence. Patients receive mirvetuximab soravtansine, an FRα-targeted antibody–drug conjugate delivering the DM4 microtubule inhibitor, IV every 3 weeks until progression or toxicity.

ClinicalTrials.gov ID: NCT03832361

Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or recurrent endometrial cancer (multiple histologies) after ≥1 prior cytotoxic line, ECOG 0–2, receive atezolizumab (PD‑L1 inhibitor) plus ONC201/dordaviprone, an investigational DRD2 antagonist and ClpP agonist that activates the integrated stress response to promote tumor apoptosis and immunogenicity. Nonrandomized dose-finding with expansion; cohorts stratified by obesity (BMI >30 vs ≤29.9); prior PD-(L)1 or ONC201 not allowed.

ClinicalTrials.gov ID: NCT05542407

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adult women with histologically confirmed locally advanced or metastatic cervical cancer that has progressed or been intolerant to ≥1 prior systemic therapy, with measurable disease and ECOG 0–1. Patients receive pembrolizumab (PD‑1 inhibitor) plus lenvatinib (oral multikinase inhibitor of VEGFR/FGFR/PDGFR/RET/KIT) aiming to enhance antitumor immunity by counteracting VEGF-mediated immunosuppression.

ClinicalTrials.gov ID: NCT04865887

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for Mismatch Repair Proficient (pMMR) Recurrent/Unresectable Endometrial Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with biopsy-proven pMMR endometrial carcinoma that is recurrent after surgery or de novo unresectable, with measurable disease confined to the pelvis/vagina and no extra-pelvic disease, ECOG 0–2, and no prior pelvic radiation. Treatment combines pembrolizumab (PD-1 inhibitor) with dose-escalated lenvatinib (multikinase inhibitor of VEGFR/FGFR/PDGFR/RET/KIT) given concurrently with hypofractionated pelvic EBRT.

ClinicalTrials.gov ID: NCT05603910

A Single-Center, Open-Label, Single-Arm, Phase I Study With Dose Expansion Cohort of Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, primary peritoneal, or endometrial cancer in adult women (PS 0–1) treated with sacituzumab govitecan (Trop-2–directed ADC delivering SN-38, a topoisomerase I inhibitor) combined with fixed-dose cisplatin every 21 days. Separate ovarian and endometrial cohorts with dose-finding followed by expansion to assess response.

ClinicalTrials.gov ID: NCT06040970

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with RAI-avid differentiated thyroid cancer after thyroidectomy with persistent/recurrent or metastatic disease undergo 124I-PET/CT dosimetry under two TSH-stimulation methods (recombinant human TSH vs thyroid hormone withdrawal), then receive patient-specific maximum safe-dose 131I therapy based on THW dosimetry. The study evaluates per-lesion and whole-body dosimetry and correlates predicted lesional dose with subsequent treatment response.

ClinicalTrials.gov ID: NCT03841617

Phase Ib Study of Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy (SBRT) in Patients With Locoregionally Recurrent, Refractory, or Oligometastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locoregionally recurrent, refractory, or oligometastatic (≤4 lesions) HNSCC (non-nasopharyngeal; CPS >1%) receive losartan lead-in, SBRT to involved sites, then pembrolizumab; prior RT/systemic therapy allowed but no prior PD‑1/PD‑L1 and no current ACEi/ARB. Losartan (angiotensin II type 1 receptor blocker) is used to remodel tumor stroma and enhance radiation/immunotherapy efficacy, followed by PD‑1 blockade with pembrolizumab.

ClinicalTrials.gov ID: NCT06211335

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/metastatic non-uveal melanoma or recurrent/metastatic HNSCC that progressed on or within 12 weeks of prior anti–PD-1 therapy receive nivolumab plus daily cabozantinib, with enrollment stratified by tumor mutational burden and Tumor Inflammation Score. Cabozantinib is a multikinase inhibitor (MET/VEGFR2/AXL) intended to disrupt angiogenesis and the immunosuppressive microenvironment to synergize with PD-1 blockade.

ClinicalTrials.gov ID: NCT05136196